|
1
|
Inaba H, Greaves M and Mullighan CG: Acute
lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhojwani D and Pui CH: Relapsed childhood
acute lymphoblastic leukaemia. Lancet Oncol. 14:e205–217. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Vlierberghe P and Ferrando A: The
molecular basis of T cell acute lymphoblastic leukemia. J Clin
Invest. 122:3398–3406. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martelli AM, Lonetti A, Buontempo F, et
al: Targeting signaling pathways in T-cell acute lymphoblastic
leukemia initiating cells. Adv Biol Regul. 56:6–21. Apr
30–2014.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koo CY, Muir KW and Lam EW: FOXM1: From
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar
|
|
7
|
Priller M, Pöschl J, Abrão L, et al:
Expression of FoxM1 is required for the proliferation of
medulloblastoma cells and indicates worse survival of patients.
Clin Cancer Res. 17:6791–6801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xue YJ, Xiao RH, Long DZ, et al:
Overexpression of FoxM1 is associated with tumor progression in
patients with clear cell renal cell carcinoma. J Transl Med.
10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xia JT, Wang H, Liang LJ, et al:
Overexpression of FOXM1 is associated with poor prognosis and
clinicopathologic stage of pancreatic ductal adenocarcinoma.
Pancreas. 41:629–635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu N, Jia D, Chen W, et al: FoxM1 is
associated with poor prognosis of non-small cell lung cancer
patients through promoting tumor metastasis. PLoS One.
8:e594122013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Qiu W, Liu B, et al: Forkhead box
transcription factor 1 expression in gastric cancer: FOXM1 is a
poor prognostic factor and mediates resistance to docetaxel. J
Transl Med. 11:2042013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu LL, Zhang DH, Mao X, Zhang XH and
Zhang B: Over-expression of FoxM1 is associated with adverse
prognosis and FLT3-ITD in acute myeloid leukemia. Biochem Biophys
Res Commun. 446:280–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Halasi M and Gartel AL: Suppression of
FOXM1 sensitizes human cancer cells to cell death induced by
DNA-damage. PLoS One. 7:e317612012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura S, Hirano I, Okinaka K, et al:
The FOXM1 transcriptional factor promotes the proliferation of
leukemia cells through modulation of cell cycle progression in
acute myeloid leukemia. Carcinogenesis. 31:2012–2021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang X, Zeng J, Zhou M, et al: The tumor
suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid
leukemia. Mol Cancer. 11:562012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mencalha AL, Binato R, Ferreira GM, Du
Rocher B and Abdelhay E: Forkhead box M1 (FoxM1) gene is a new
STAT3 transcriptional factor target and is essential for
proliferation, survival and DNA repair of K562 cell line. PloS one.
7:e481602012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bhat UG, Halasi M and Gartel AL: FoxM1 is
a general target for proteasome inhibitors. PLoS One. 4:e65932009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hegde NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hedge NS, Sanders DA, Rodriguez R and
Balasubramanian S: The transcription factor FOXM1 is a cellular
target of the natural product thiostrepton. Nat Chem. 3:725–731.
2011. View Article : Google Scholar
|
|
21
|
Gartel AL: Thiostrepton, proteasome
inhibitors and FOXM1. Cell Cycle. 10:4341–4342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Halasi M, Schraufnagel DP and Gartel AL:
Wild-type p53 protects normal cells against apoptosis induced by
thiostrepton. Cell Cycle. 8:2850–2851. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ahmed M, Uddin S, Hussain AR, et al: FoxM1
and its association with matrix metalloproteinases (MMP) signaling
pathway in papillary thyroid carcinoma. J Clin Endocrinol Metab.
97:E1–13. 2012. View Article : Google Scholar
|
|
24
|
Wang M and Gartel AL: Micelle-encapsulated
thiostrepton as an effective nanomedicine for inhibiting tumor
growth and for suppressing FOXM1 in human xenografts. Mol Cancer
Ther. 10:2287–2297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Li X, Wang L, et al: Realgar
induces apoptosis in the chronic lymphocytic leukemia cell line
MEC1. Mol Med Rep. 8:1866–1870. 2013.PubMed/NCBI
|
|
26
|
Ji BS, He L and Liu GQ: Reversal of
p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine
derivative, in doxorubicin-resistant human myelogenous leukemia
(K562/DOX) cells. Life Sci. 77:2221–2232. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Van Vlierberghe P, A mbesi-I mpiombato A,
De Keersmaecker K, et al: Prognostic relevance of integrated
genetic profiling in adult T-cell acute lymphoblastic leukemia.
Blood. 122:74–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bhat UG, Halasi M and Gartel AL: Thiazole
antibiotics target FoxM1 and induce apoptosis in human cancer
cells. PLoS One. 4:e55922009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin J, Zheng Y, Chen K, Huang Z, Wu X and
Zhang N: Inhibition of FOXM1 by thiostrepton sensitizes
medulloblastoma to the effects of chemotherapy. Oncol Rep.
30:1739–1744. 2013.PubMed/NCBI
|
|
30
|
Halasi M and Gartel AL: FOX(M1) news - it
is cancer. Mol Cancer Ther. 12:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zaffaroni N, Pennati M and Daidone MG:
Survivin as a target for new anticancer interventions. J Cell Mol
Med. 9:360–372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou L, Jing Y, Styblo M, Chen Z and
Waxman S: Glutathione-S-transferase pi inhibits As2O3-induced
apoptosis in lymphoma cells: involvement of hydrogen peroxide
catabolism. Blood. 105:1198–1203. 2005. View Article : Google Scholar
|
|
33
|
Lourenco GJ, Lorand-Metze I, Delamain MT,
et al: Polymorphisms of glutathione S-transferase mu 1, theta 1 and
pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma.
51:2215–2221. 2010. View Article : Google Scholar
|
|
34
|
Ballerini S, Bellincampi L, Bernardini S,
Iori R, Cortese C and Federici G: Analysis of GSTP1–1 polymorphism
using real-time polymerase chain reaction. Clin Chim Acta.
329:127–132. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song YN, Guo XL, Zheng BB, et al:
Ligustrazine derivate DLJ14 reduces multidrug resistance of
K562/A02 cells by modulating GSTπ activity. Toxicol In Vitro.
25:937–943. 2011. View Article : Google Scholar : PubMed/NCBI
|
